Analyst Price Target is $2.50
▲ +47.06% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Assembly Biosciences in the last 3 months. The average price target is $2.50, with a high forecast of $3.00 and a low forecast of $2.00. The average price target represents a 47.06% upside from the last price of $1.70.
Current Consensus is
Buy
The current consensus among 2 polled investment analysts is to buy stock in Assembly Biosciences. This rating has held steady since August 2022, when it changed from a Hold consensus rating.
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
Read More